427 related articles for article (PubMed ID: 27756788)
1. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Segal NH; Logan TF; Hodi FS; McDermott D; Melero I; Hamid O; Schmidt H; Robert C; Chiarion-Sileni V; Ascierto PA; Maio M; Urba WJ; Gangadhar TC; Suryawanshi S; Neely J; Jure-Kunkel M; Krishnan S; Kohrt H; Sznol M; Levy R
Clin Cancer Res; 2017 Apr; 23(8):1929-1936. PubMed ID: 27756788
[No Abstract] [Full Text] [Related]
2. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Khushalani NI; Ott PA; Ferris RL; Cascone T; Schadendorf D; Le DT; Sharma MR; Barlesi F; Sharfman W; Luke JJ; Melero I; Lathers D; Neely J; Suryawanshi S; Sanyal A; Holloway JL; Suryawanshi R; Ely S; Segal NH
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458639
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
4. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Timmerman J; Herbaux C; Ribrag V; Zelenetz AD; Houot R; Neelapu SS; Logan T; Lossos IS; Urba W; Salles G; Ramchandren R; Jacobson C; Godwin J; Carpio C; Lathers D; Liu Y; Neely J; Suryawanshi S; Koguchi Y; Levy R
Am J Hematol; 2020 May; 95(5):510-520. PubMed ID: 32052473
[TBL] [Abstract][Full Text] [Related]
5. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN; Meulendijks D; Siu LL; Karanikas V; Mau-Sorensen M; Schellens JH; Jonker DJ; Hansen AR; Simcox ME; Schostack KJ; Bottino D; Zhong H; Roessler M; Vega-Harring SM; Jarutat T; Geho D; Wang K; DeMario M; Goss GD
Clin Cancer Res; 2015 Jan; 21(2):258-66. PubMed ID: 25388164
[TBL] [Abstract][Full Text] [Related]
6. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
7. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
Hong DS; Hui D; Bruera E; Janku F; Naing A; Falchook GS; Piha-Paul S; Wheler JJ; Fu S; Tsimberidou AM; Stecher M; Mohanty P; Simard J; Kurzrock R
Lancet Oncol; 2014 May; 15(6):656-66. PubMed ID: 24746841
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
Herbst RS; Eckhardt SG; Kurzrock R; Ebbinghaus S; O'Dwyer PJ; Gordon MS; Novotny W; Goldwasser MA; Tohnya TM; Lum BL; Ashkenazi A; Jubb AM; Mendelson DS
J Clin Oncol; 2010 Jun; 28(17):2839-46. PubMed ID: 20458040
[TBL] [Abstract][Full Text] [Related]
10. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.
Papadopoulos KP; Gluck L; Martin LP; Olszanski AJ; Tolcher AW; Ngarmchamnanrith G; Rasmussen E; Amore BM; Nagorsen D; Hill JS; Stephenson J
Clin Cancer Res; 2017 Oct; 23(19):5703-5710. PubMed ID: 28655795
[No Abstract] [Full Text] [Related]
12. Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies.
Almhanna K; Kalebic T; Cruz C; Faris JE; Ryan DP; Jung J; Wyant T; Fasanmade AA; Messersmith W; Rodon J
Clin Cancer Res; 2016 Oct; 22(20):5049-5057. PubMed ID: 27178743
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
Vonderheide RH; Flaherty KT; Khalil M; Stumacher MS; Bajor DL; Hutnick NA; Sullivan P; Mahany JJ; Gallagher M; Kramer A; Green SJ; O'Dwyer PJ; Running KL; Huhn RD; Antonia SJ
J Clin Oncol; 2007 Mar; 25(7):876-83. PubMed ID: 17327609
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
15. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
LoRusso P; Jänne PA; Oliveira M; Rizvi N; Malburg L; Keedy V; Yee L; Copigneaux C; Hettmann T; Wu CY; Ang A; Halim AB; Beckman RA; Beaupre D; Berlin J
Clin Cancer Res; 2013 Jun; 19(11):3078-87. PubMed ID: 23591447
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.
Haluska P; Menefee M; Plimack ER; Rosenberg J; Northfelt D; LaVallee T; Shi L; Yu XQ; Burke P; Huang J; Viner J; McDevitt J; LoRusso P
Clin Cancer Res; 2014 Sep; 20(18):4747-57. PubMed ID: 25024259
[TBL] [Abstract][Full Text] [Related]
19. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Rosen LS; Goldman JW; Algazi AP; Turner PK; Moser B; Hu T; Wang XA; Tuttle J; Wacheck V; Wooldridge JE; Banck M
Clin Cancer Res; 2017 Apr; 23(8):1910-1919. PubMed ID: 27803065
[No Abstract] [Full Text] [Related]
20. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
